Top

Cancer Causes & Control

Published in:

01-10-2009 | Original Paper

Total dietary antioxidant index and survival in patients with glioblastoma multiforme

Authors: Dora Il’yasova, Jennifer E. Marcello, Lucie McCoy, Terri Rice, Margaret Wrensch

Published in: Cancer Causes & Control | Issue 8/2009

Abstract

Objectives

The role of antioxidants in survival of cancer patients is controversial. No data on the relationships between antioxidant intake and survival of glioma patients are available. Our objective was to examine such association in a large series of cases.

Methods

The study population includes 814 glioblastoma multiforme cases that were newly diagnosed, histologically confirmed, aged 20 or older, and residing in the San Francisco Bay Area at diagnosis. Cases were identified via the regional cancer registry’s rapid case ascertainment system during 1991–1994 (series I), 1997–2000 (series II), and 2001–2004 (series III). Daily dietary antioxidant intake at diagnosis was assessed via food-frequency questionnaire and was expressed as total antioxidant index, calculated based on Trolox equivalent per gram of food. In addition, the study collected information on supplements/vitamin intake.

Results

Overall, our results indicated no consistent, significant association of survival with dietary antioxidant intake or its combination with vitamin supplements. However, in series III, we observed a significant association between higher antioxidant index and better survival: HR = 0.58 (95% CI: 0.46, 0.74) for each unit of antioxidant index on a log-scale.

Conclusions

Although it is possible that this is a chance finding, the association between dietary antioxidants and survival in the most recently recruited patients warrants further investigations.

Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507. doi:10.1056/NEJMra0708126 PubMedCrossRef

Tedeschi-Blok N, Lee M, Sison JD, Miike R, Wrensch M (2006) Inverse association of antioxidant and phytoestrogen nutrient intake with adult glioma in the San Francisco Bay Area: a case–control study. BMC Cancer 6:148. doi:10.1186/1471-2407-6-148 PubMedCrossRef

Hu J, La VC, Negri E et al (1999) Diet and brain cancer in adults: a case–control study in northeast China. Int J Cancer 81:20–23. doi:10.1002/(SICI)1097-0215(19990331)81:1<20::AID-IJC4>3.0.CO;2-2 PubMedCrossRef

Chen H, Ward MH, Tucker KL et al (2002) Diet and risk of adult glioma in eastern Nebraska, United States. Cancer Causes Control 13:647–655. doi:10.1023/A:1019527225197 PubMedCrossRef

Lee M, Wrensch M, Miike R (1997) Dietary and tobacco risk factors for adult onset glioma in the San Francisco Bay Area (California, USA). Cancer Causes Control 8:13–24. doi:10.1023/A:1018470802969 PubMedCrossRef

Schwartzbaum JA, Fisher JL, Goodman J, Octaviano D, Cornwell DG (1999) Hypotheses concerning roles of dietary energy, cured meat, and serum tocopherols in adult glioma development. Neuroepidemiology 18:156–166. doi:10.1159/000026207 PubMedCrossRef

Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB (2008) Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100:773–783. doi:10.1093/jnci/djn148 PubMedCrossRef

Lissoni P, Meregalli S, Nosetto L et al (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53:43–46PubMedCrossRef

Conklin KA (2004) Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3:294–300. doi:10.1177/1534735404270335 PubMedCrossRef

10.

Zhong W, Yan T, Lim R, Oberley LW (1999) Expression of superoxide dismutases, catalase, and glutathione peroxidase in glioma cells. Free Radic Biol Med 27:1334–1345. doi:10.1016/S0891-5849(99)00181-1 PubMedCrossRef

11.

Pu PY, Lan J, Shan SB et al (1996) Study of the antioxidant enzymes in human brain tumors. J Neurooncol 29:121–128. doi:10.1007/BF00182134 PubMedCrossRef

12.

Nordfors K, Haapasalo J, Helen P et al (2007) Peroxiredoxins and antioxidant enzymes in pilocytic astrocytomas. Clin Neuropathol 26:210–218PubMed

13.

Khalil AA (2007) Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 98:201–213. doi:10.1111/j.1349-7006.2007.00374.x PubMedCrossRef

14.

Preuss M, Girnun GD, Darby CJ, Khoo N, Spector AA, Robbins MEC (2000) Role of antioxidant enzyme expression in the selective cytotoxic response of glioma cells to [gamma]-linolenic acid supplementation. Free Radic Biol Med 28:1143–1156. doi:10.1016/S0891-5849(00)00210-0 PubMedCrossRef

15.

Smith PS, Zhao W, Spitz DR, Robbins ME (2007) Inhibiting catalase activity sensitizes 36B10 rat glioma cells to oxidative stress. Free Radic Biol Med 42:787–797. doi:10.1016/j.freeradbiomed.2006.11.032 PubMedCrossRef

16.

Smith-Pearson PS, Kooshki M, Spitz DR, Poole LB, Zhao W, Robbins ME (2009) Decreasing peroxiredoxin II expression decreases glutathione, alters cell cycle distribution, and sensitizes glioma cells to ionizing radiation and H2O2. Free Radic Biol Med (in press, corrected proof)

17.

Jarvela S, Bragge H, Paunu N et al (2006) Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. J Neurooncol 77:131–140. doi:10.1007/s11060-006-9118-0 PubMedCrossRef

18.

Okcu MF, Selvan M, Wang LE et al (2004) Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 10:2618–2625. doi:10.1158/1078-0432.CCR-03-0053 PubMedCrossRef

19.

Pouliquen D, Olivier C, Hervouet E et al (2008) Dietary prevention of malignant glioma aggressiveness, implications in oxidant stress and apoptosis. Int J Cancer 123:288–295. doi:10.1002/ijc.23513 PubMedCrossRef

20.

Cao G, Sofic E, Prior RL (1996) Antioxidant capacity of tea and common vegetables. J Agric Food Chem 44:3426–3431. doi:10.1021/jf9602535 CrossRef

21.

Pellegrini N, Salvatore S, Valtuena S et al (2007) Development and validation of a food frequency questionnaire for the assessment of dietary total antioxidant capacity. J Nutr 137:93–98PubMed

22.

Rautiainen S, Serafini M, Morgenstern R, Prior RL, Wolk A (2008) The validity and reproducibility of food-frequency questionnaire-based total antioxidant capacity estimates in Swedish women. Am J Clin Nutr 87:1247–1253PubMed

23.

Serafini M, Del RD (2004) Understanding the association between dietary antioxidants, redox status and disease: is the total antioxidant capacity the right tool? Redox Rep 9:145–152. doi:10.1179/135100004225004814 PubMedCrossRef

24.

Wang H, Cao G, Prior RL (1996) Total antioxidant capacity of fruits. J Agric Food Chem 44:701–705. doi:10.1021/jf950579y CrossRef

25.

Krishnan G, Felini M, Carozza SE, Miike R, Chew T, Wrensch M (2003) Occupation and adult gliomas in the San Francisco Bay Area. J Occup Environ Med 45:639–647. doi:10.1097/01.jom.0000069245.06498.48 PubMedCrossRef

26.

Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M (2002) History of allergies among adults with glioma and controls. Int J Cancer 98:609–615. doi:10.1002/ijc.10239 PubMedCrossRef

27.

Wrensch M, Lee M, Miike R et al (1997) Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol 145:581–593PubMed

28.

Wrensch M, Kelsey KT, Liu M et al (2004) Glutathione-S-transferase variants and adult glioma. Cancer Epidemiol Biomarkers Prev 13:461–467PubMed

29.

Wrensch M, McMillan A, Wiencke J et al (2007) Nonsynonymous coding single-nucleotide polymorphisms spanning the genome in relation to glioblastoma survival and age at diagnosis. Clin Cancer Res 13:197–205. doi:10.1158/1078-0432.CCR-06-1199 PubMedCrossRef

30.

Rice-Evans CA, Miller NJ (1996) Antioxidant activities of flavonoids as bioactive components of food. Biochem Soc Trans 24:790–795PubMed

31.

Mason WP, Cairncross JG (2005) Drug insight: temozolomide as a treatment for malignant glioma[mdash]impact of a recent trial. Nat Clin Pract Neurol 1:88–95. doi:10.1038/ncpneuro0045 PubMedCrossRef

Title: Total dietary antioxidant index and survival in patients with glioblastoma multiforme
Authors: Dora Il’yasova
Jennifer E. Marcello
Lucie McCoy
Terri Rice
Margaret Wrensch
Publication date: 01-10-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 8/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9338-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2009

Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California

Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors

Investigating reversals of association for utilization of recent mammography among Hispanic and Non-Hispanic Black women

Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma

Physical activity in adolescence and testicular germ cell cancer risk

Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States

Keynote webinar | Spotlight on antibody–drug conjugates in cancer